Study Phase: Phase I Trial

A Comparative Study to Evaluate the Effects and Mechanism of Action of Dysport®, Botox® and Xeomin® in the Extensor Digitorum Brevis Model in Healthy Adult Male Participants

Study aimed at comparing the pharmacodynamic profile (including duration of action) of three commercialized toxins by measuring the action potential of the injected muscle (extensor digitorum brevis)

Study to evaluate the safety and activity (including distribution) of 177Lu-3BP-227 in subjects with solid tumours expressing neurotensin receptor type 1.

This study was being conducted to advance new treatment for patients with metastatic or locally advanced cancers expressing Neurotensin receptor 1 (NTSR1). This study was a first administration of a radioactive drug called 177Lu-3BP-227 to patients under controlled conditions of a clinical study. The purpose of this study is to evaluate how safe this investigational

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

The purpose of this clinical phase I/II study is to investigate the safety and tolerability of 177Lu-OPS201 used for the treatment of patients with neuroendocrine tumors (NETs). Secondary objectives of these study are the assessment of biodistribution, dosimetry and preliminary efficacy of 177Lu-OPS201.

Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal Function

Renal excretion is a minor elimination route of telotristat etiprate. So this trial is intended to assess the drug behaviour in subjects with decreased renal function. This is a staged study with Part B contingent upon the results of Part A. Part A will enrol a total of 16 subjects, eight with severely impaired renal

Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects

The purpose of the protocol is to assess the pharmacokinetics, safety and tolerability of a single dose of telotristat etiprate in subjects with various stages of hepatic impairment compared to healthy control subjects.

A Study to Evaluate the Effect of Food on the Level of Circulating Elafibranor in Healthy Participants after Intake of a Single Tablet

This study will evaluate the effects of food on how much test drug is able to access the circulation and reach the target area (known as bioavailability). The test drug, elafibranor (IPN60190), is in development for the treatment of primary biliary cholangitis (PBC). PBC is a rare, long-term autoimmune disease of the liver. An autoimmune

Study to Compare the Level of Elafibranor in Blood after Repeat Administration in Japanese and non-Asian Healthy Participants

This study is intended to measure the blood levels of Elafibranor and one of its metabolites in Japanese and non-Asian Healthy Participants, to be able to compare how the body absorbs, distributes, and eliminates Elafibranor after Repeat Administration, in order to support inclusion of Japanese patients in the planned clinical studies with elafibranor.

Study to compare the levels of IPN60170 (mesdopetam) in blood in healthy Japanese, Chinese and Non-Asian participants after administration of two different doses of IPN60170

This Phase 1 study is part of the global development plan, which includes plans to seek marketing approval of IPN60170 in Japan and China. The Japan Pharmaceuticals and Medical Devices Agency (PMDA) and the National Medical Products Administration (NMPA) in China request that the full pharmacokinetic (PK) profile of a new drug entity be assessed

A study of radiolabelled IPN60170 (Mesdopetam) elimination pathways in healthy adult male participants

The test treatment, IPN60170 (Mesdopetam), is in development for the treatment of levodopa -induced dyskinesia in Parkinson’s Disease. Parkinson’s Disease is a progressive nervous system condition that affects movement, caused by nerve cells in a specific area of the brain called the substantia nigra deteriorating or dying. Dyskinesia is uncontrolled or involuntary muscle movements that

A study to evaluate the effect of fluvoxamine, paroxetine, and smoking on a single IPN60170 (mesdopetam) dose in healthy male participants

This study will investigate the pharmacokinetics (PK), safety, and tolerability of IPN60170 and its metabolites in smokers and nonsmokers healthy male participants. IPN60170 is being developed as a potential treatment to reduce levodopa-induced dyskinesia (LID) and psychosis in patients with Parkinson’s Disease (PD).